• Business News
  • Insurance
  • Saving
  • Share Market 5Paisa
  • Loan
  • Mutual Funds
  • Investment
  • Real Estate
  • Crypto coindcx
    • हिन्दी
    • తెలుగు
    • मराठी
    • বাংলা
    • ગુજરાતી
    • ಕನ್ನಡ
  • Close
  • Daily Show
    • 2+2=5
    • Take it Easy
    • Red Alert
    • Formula Guru
    • Money Gyan
    • Money Central
    • Money time
    • Jhatpat
  • Weekly Show
    • Money Comics
    • Economicom
    • Realty Check
    • Smile and pay
    • Money Tales
    • Spend Wise
    • Companynama
  • Insurance
  • Savings
  • Share Market 5Paisa
  • Loan
  • Crypto coindcx
  • Investment
  • Mutual Funds
  • Real Estate
  • Tax
  • Exclusive
  • Home » News » Covid Update » Delhi asks Centre to share vaccine formula to raise production

Delhi asks Centre to share vaccine formula to raise production

As many as 125 centres administering Covaxin to 18-44 age group are likely to be closed down by Wednesday as the Delhi government did not receive new stock of the vaccine till Tuesday evening

  • Press Trust of India
  • Publish Date - May 11, 2021 / 09:20 PM IST
Delhi asks Centre to share vaccine formula to raise production
India’s arsenal of vaccines consists of SII-AstraZeneca-made Covishield, Bharat Biotech’s Covaxin and Russia’s Sputnik.

New Delhi: The Delhi government Tuesday said it will have to shut a large number of Covid-19 jab centres due to a shortage of shots and urged the Centre to use its special power to allow more firms to manufacture vaccines, while also announced the AAP dispensation will float a global tender to procure additional doses.

As many as 125 centres administering Covaxin to 18-44 age group are likely to be closed down by Wednesday as the Delhi government did not receive new stock of the vaccine till Tuesday evening.

Chief Minister Arvind Kejriwal wrote to Prime Minister Narendra Modi, saying the Centre should share the vaccine formula of the two manufacturers with other capable pharmaceutical companies to scale up production in the country.

In his letter to Modi, Kejriwal said the entire country can be provided a “safety cover” by allowing more companies to manufacture the vaccines on a war footing in preparation for an anticipated third wave of the pandemic. He said the Centre can also terminate the monopoly on vaccine production through the patent law.

There are two vaccine makers in the country currently — Bharat Biotech and Serum Institute of India — which are manufacturing Covaxin and Covishield, respectively.

These two firms can be given royalty from the profit of other companies for the use of their original formulas, Kejriwal said.

“Presently, only two companies are manufacturing vaccines in India. Providing vaccines to the whole country through two companies only is not possible. It requires ramping up vaccine manufacturing at war footing. I request you to grant permission for mass production of the vaccines,” he wrote in his letter to Modi.

Faced with the acute shortage of vaccines, Deputy Chief Minister Manish Sisodia said the Delhi government will float a global tender for procuring COVID-19 vaccines.

Only three vaccines have so far been approved to be sold in India — Covaxin, Coveshield and Sputnik V. Sputnik V has been approved to be imported from Russia by Dr Reddy’s, but is yet to be widely available in the country.

Addressing a press conference here, Sisodia alleged that the BJP-ruled Centre was “forcing” state governments to invite global tenders for vaccine procurement.

The Central government wants the states to compete and fight with each other in the international market for vaccines, Sisodai alleged.

“It is the role and responsibility of the Central government to integrate the needs of all States and procure vaccines through a global tender for India instead of leaving states to fight in an international marketplace for vaccines,” Sisodia said.

Sisodia appealed to the Centre to take cognisance of the crisis and immediately begin a vaccine programme along the lines of the Pulse Polio Programme.

During a press briefing on Tuesday, Kejriwal said the Centre has the power to share COVID-19 formula with other companies to scale up vaccine production in the country.

There is an urgent need to ramp up the manufacturing of vaccines on a war footing while developing a national policy to inoculate everyone in the next few months, he said.

“Delhi is facing a shortage of vaccines. Some states have not even started inoculation because they do not have the required number of doses. The vaccine shortage has become a big challenge for the country,” the Aam Aadmi Party (AAP) supremo said.

He said the Centre should ensure that all the vaccine manufacturing plants in the country start producing COVID-19 vaccines.

“The two vaccine companies in the country are currently producing around six-seven crore doses per month. At this rate, it will take two years to vaccinate everyone. Who knows how many waves of COVID will pass us by then and what will be extent of the destruction.

“The Centre should take the vaccine formula from these two companies and provide it to all those companies that can safely manufacture the vaccines,” Kejriwal said.

“We have excellent industrialists, pharmaceutical companies that are the largest in the world and the best scientists. I believe that if given a chance, they will extend their full cooperation,” he added.

Meanwhile, AAP MLA Atishi said 125 centres administering Covaxin for the 18-44 age group are likely to be shut from Wednesday since the national capital has run out of Covaxin stock for them.

The national capital on Tuesday reported 12,481 new cases, 347 more fatalities with a positivity rate of 17.76%, the Health Department said. The number of new cases reported on a single day is the lowest since April 12 while the positivity rate is the lowest since April 14, when it stood at 15.9%. The positivity rate has remained above the 20% mark since April 17.

Download Money9 App for the latest updates on Personal Finance.

follow us

  • Facebook
  • Twitter
  • LinkedIn
  • Telegram
  • Youtube
  • Instagram

also read

  • Covid first wave led to increase in antibiotic misuse in India: Study

    Covid first wave led to increase in antibiotic misuse in India: Study

  • Centre rushes teams to six states reporting a high number of Covid cases

    Centre rushes teams to six states reporting a high number of Covid cases

Read more news on

  • Arvind Kejriwal
  • Covaxin
  • Covid vaccine
  • Covid vaccine shortage
  • covishield

Latest Video

SEE MORE
Why mutual fund investment is falling ever since FIIs have made a comeback?

Why mutual fund investment is falling ever since FIIs have made a comeback?

Updated: August 12, 2022
Tariff increase on cards; 5g tariff plans in India to make data expensive

Tariff increase on cards; 5g tariff plans in India to make data expensive

Updated: August 11, 2022
Why wheat prices won't fall even if wheat import duty is reduced?

Why wheat prices won’t fall even if wheat import duty is reduced?

Updated: August 10, 2022
Know Nifty 50 forecast, Sensex 30 forecast

Know Nifty 50 forecast, Sensex 30 forecast

Updated: August 9, 2022
Know the reason why onion prices are falling and current problems faced by onion farmers

Know the reason why onion prices are falling and current problems faced by onion farmers

Updated: August 5, 2022
Why clothes are not becoming cheaper despite  fall in cotton prices?

Why clothes are not becoming cheaper despite fall in cotton prices?

Updated: August 4, 2022
When will attrition in IT Sector and Tech Startups stop?

When will attrition in IT Sector and Tech Startups stop?

Updated: August 3, 2022
How will government's decision to implement 5% GST on non-branded food items impact you?

How will government’s decision to implement 5% GST on non-branded food items impact you?

Updated: August 2, 2022
Open in App

Related

  • Delhi Govt to cut VAT on petrol, diesel soon: Kejriwal

    Delhi Govt to cut VAT on petrol, diesel soon: Kejriwal

  • WHO grants emergency usage listing for Covaxin

    WHO grants emergency usage listing for Covaxin

  • Next challenge, make vaccines work against new variants: Adar Poonawalla

    Next challenge, make vaccines work against new variants: Adar Poonawalla

  • Covaxin for children likely to be rolled out in phases: Report

    Covaxin for children likely to be rolled out in phases: Report

  • Covaxin gets emergency use approval for kids aged 2-18 years

    Covaxin gets emergency use approval for kids aged 2-18 years

  • India records 18,132 fresh Covid-19 cases; lowest in 215 days

    India records 18,132 fresh Covid-19 cases; lowest in 215 days

Videos

  • Tariff increase on cards; 5g tariff plans in India to make data expensive
    Analysis

    Data To Make Your Pocket Light

  • Ministry of Civil Aviation removes airfare bands with effect from August 31, 2022
    Bulletin

    Freedom For Airlines in Ticket Prices

  • How does gadget insurance work? What does gadget insurance cover?
    Savings

    Protect Your Costly Gadgets This Way

  • What is the difference between Bulk and Block Deal?
    Helpline

    What is the difference between Bulk and Block Deal?

  • Why wheat prices won’t fall even if wheat import duty is reduced?
    Analysis

    The Battle For Indian Wheat Market

  • TV9 Sites

  • TV9 Hindi
  • TV9Telugu.com
  • TV9 Marathi
  • TV9 Gujarati
  • TV9 Kannada
  • TV9 Bangla
  • News9 Live
  • Know this india
  • Money9 Sites

  • Money9 Hindi
  • Money9 English
  • Money9 Marathi
  • Money9 Telugu
  • Money9 Gujarati
  • Money9 Kannada
  • Money9 Bangla
  • Topics

  • Insurance
  • Savings
  • Loan
  • Stocks
  • Mutual Funds
  • Real Estate
  • Tax
  • Crypto
  • Exclusive
  • Daily Shows

  • 2+2=5
  • Take it Easy
  • Red Alert
  • Formula Guru
  • Money Gyan
  • Money Central
  • Jhatpat
  • Money time
  • Weekly Shows

  • Money Comics
  • Economicom
  • Realty Check
  • Smile and pay
  • Money Tales
  • Companynama
  • Spend Wise
  • Follow us

  • FaceBook
  • Twitter
  • Youtube
  • Instagram
  • Linkedin
  • Download App

  • Andorid
  • ios
  • Contact Us
  • About Us
  • Advertise With Us
  • Privacy & Cookies Notice
  • Complaint Redressal
  • Copyright © 2022 Money9. All rights reserved.